37 results about "Glucose / Sodium Chloride Injection" patented technology

The invention provides a glucose and sodium chloride injection, which is prepared from glucose 50g (or 100g, 200g, 500g), sodium chloride 9g and balancing water for injection to 1000ml through mixing, inspecting, encapsulating, sterilizing, lamp checking and packaging.

The invention relates to a children pharmaceutical composition containing ceftriaxone sodium, namely a pharmaceutical combined preparation containing ceftriaxone sodium and a low-sodium carrier infusion solution, and particularly relates to a combined package. The children pharmaceutical composition comprises ceftriaxone sodium for injection and the low-sodium carrier infusion solution. The low-sodium carrier infusion solution contains a glucose and sodium chloride injection (15-200):1, a glucose and sodium chloride potassium chloride injection (15-200):1: (0-1) and the like. Compared with a mixture of ceftriaxone sodium and the low-sodium carrier infusion solution, the children pharmaceutical composition has the advantages that clinical application steps are simplified, clinical risks generated because kidneys of children are not developed to be mature and overmuch sodium in blood cannot be metabolized are reduced, and the clinical application quality and safety performance of children medication are improved.

The invention discloses a process for pretreating glucose and sodium chloride injection, and belongs to the technical field of injection. The method comprises the following steps: (1) weighing raw materials; (2) dissolving the raw materials, namely a) adding sodium hydrogen sulfite, magnesium chloride, calcium chloride, sodium chloride and zinc sulfate into injecting water at 30-40 DEG C; (b) adding dipotassium phosphate, glucose, fructose, xylitol and sodium acetate into the injecting water at 50-60 DEG C; and (c) mixing the solution, adding citric acid and activated carbon, insulating and adsorbing; (3) decarburizing, delivering to a diluting tank; (4) complementing injecting water, and regulating the pH value to 6.5-7.5; (5) filling bags after rough filtration and fine filtration; and (6) sterilizing at 122 DEG C for 3-5 minutes. According to the process, raw materials are dissolved in batches with different dissolving temperatures, the dissolving speed is increased, the temperature is reasonably controlled, energy consumption and cost are reduced, the solution is uniformly mixed, and generation of glucose degraded products can be effectively reduced.

The invention provides an NK cell low-temperature preservation re-infusion liquid. According to the invention, a glucose and sodium chloride injection is added into the NK cell low-temperature preservation re-infusion liquid to serve as a diluent/buffer liquid, so that the effects of maintaining the pH value, the ion osmotic pressure and the colloid osmotic pressure and providing energy glucose for cells are achieved; the added human serum albumin can maintain the constant osmotic pressure of plasma colloid and supply nutrition; the added vitamin C can promote antibody and collagen formation and tissue repair, and meanwhile, the vitamin C also has the effects of resisting oxidation, resisting free radicals and inhibiting tyrosinase formation, so that the oxidative damage of cells can be reduced, and the accumulation of peroxides in the cells can be quickly relieved. According to the NK cell low-temperature preservation re-infusion liquid, the survival rate of NK cells can be kept at 80% or above after the NK cells are preserved for 48 h at the temperature of 4 DEG C, and a preparation can be directly re-infused.

The invention belongs to the technical field of medicine, and particularly relates to a cefotiam hydrochloride compound, a method for preparing the same and a pharmaceutical composition with the cefotiam hydrochloride compound. The cefotiam hydrochloride compound is cefotiam hydrochloride trihydrate, and a structural formula of the cefotiam hydrochloride compound is shown. The cefotiam hydrochloride compound, the method and the pharmaceutical composition have the advantages that crystals of the cefotiam hydrochloride trihydrate are good in flowability, injection cefotiam hydrochloride made of the crystals of the cefotiam hydrochloride trihydrate, 0.9% sodium chloride injection, 5% glucose injection and 5% glucose and sodium chloride injection can be compatible with one another to obtain liquor, and the liquor is excellent in stability after being placed at the room temperature for 4h.

The invention discloses a method for determining content of glucose and sodium chloride in sodium chloride and dextrose injection. The method comprises the following steps: step1, performing sample pretreatment, and diluting 50mg of sodium chloride and dextrose injection with 40ml of water, and adding acetonitrile to constant volume of 100ml; step2, analyzing by high performance liquid chromatography; parameters of the high performance liquid chromatography are set as follows: mobile phase: acetonitrile-water; flow rate: 1ml/min; column temperature: 40 DEG C; chromatographic column: Thermo Acclaim mixed-matrix chromatographic column, 4.6mum*250mm, 5mum. The invention aims at providing the method for determining the content of the glucose and the sodium chloride in the sodium chloride and dextrose injection, which is accurate in determination and simple in operation.

The invention relates to a child type amoxicillin sulbactam sodium medicine composition, namely an amoxicillin sulbactam sodium and low-sodium carrier transfusion medicine combination preparation, and in particular to combined application packaging. The medicine composition comprises amoxicillin sulbactam sodium for injection and a low-sodium carrier transfusion solution. The low-sodium carrier transfusion solution contains a sodium chloride and dextrose injection (15-200:1), a glucose and sodium chloride potassium chloride injection (15-200:1:0-1) and the like. According to the composition, compared with the mode that the amoxicillin sulbactam sodium and the low-sodium carrier transfusion are mixed and used in a compatibility manner, the clinical application steps are simplified; and clinic risks caused by the fact that the kidney of a child is not mature, so that the child does not have the ability to metabolize excessive sodium in blood are reduced, and the clinic application quality and the clinic application safety of child pharmacy are improved.

The invention relates to a children pharmaceutical composition containing ceftazidime, namely a pharmaceutical combined preparation containing ceftazidime and a low-sodium carrier infusion solution and particularly relates to a combined package. The children pharmaceutical composition comprises ceftazidime for injection and the low-sodium carrier infusion solution. The low-sodium carrier infusion solution contains a glucose and sodium chloride injection (15-200):1, a glucose and sodium chloride potassium chloride injection (15-200):1: (0-1) and the like. Compared with a mixture of ceftazidime and the low-sodium carrier infusion solution, the children pharmaceutical composition has the advantages that clinical application steps are simplified, clinical risks generated because kidneys of children are not developed to be mature and overmuch sodium in blood cannot be metabolized are reduced, and the clinical application quality and safety performance of children medication are improved.

The invention relates to a child-type ampicillin-sulbactam-sodium medicinal composition, i.e. a medicinal combined preparation with ampicillin sulbactam sodium and low-sodium carrier infusion fluid, especially combined application package comprising the ampicillin sulbactam sodium and the low-sodium infusion carrier fluid. The low-sodium carrier infusion fluid comprises glucose and sodium chloride injection fluid (15-200:1) and glucose and sodium-chloride potassium-chloride injection fluid (15-200:1:0-1) and the like. The child-type medicinal composition has the advantages that compared with the compatible and mixing use of the ampicillin sulbactam sodium and the low-sodium carrier infusion fluid, the clinical application steps are simplified, the clinical risks caused by incapability of metabolizing excessive sodium in blood since the kidney of a child is not matured are reduced and the clinical application quality and safety of child administration are improved.

The invention relates to a pharmaceutical cefotiam hydrochloride composition for treating infectious diseases, belonging to the technical field of medicine. The composition is composed of cefotiam hydrochloride and anhydrous sodium carbonate. The cefotiam hydrochloride is a crystal, and can obtain an X-ray powder diffractogram disclosed as Figure 1 by using Cu-Kalpha ray measurement. The cefotiam hydrochloride new crystal form provided by the invention is different from the crystal form structure in the prior art. The experimental verification surprisingly detects that the crystal compound has the advantages of high purity, favorable flowability, favorable stability, low polymer content and no hygroscopicity; and the solution, which is prepared by mixing the powder injection, a 0.9% sodium chloride injection, a 5% glucose injection and a 5% glucose sodium chloride injection and standing at room temperature for 4 hours, has favorable stability.

The present invention relates to a children type cefoxitin sodium pharmaceutical composition, especially to a combination application package, wherein the composition is a cefoxitin sodium and low-sodium carrier infusion pharmaceutical combination preparation, which comprises cefoxitin sodium for injection and a low-sodium carrier infusion, wherein the low-sodium carrier infusion contains a glucose and sodium chloride injection (15-200:1), a glucose, sodium chloride and potassium chloride injection (15-200:1:0-1) and the like. According to the present invention, the clinical application steps are simplified compared with the compatible mixing use of the cefoxitin sodium and the low-sodium carrier infusion; and the clinical risk caused by the excessive sodium positioned in the blood and incapable of being metabolized due to the children kidney achieving the immature development state is reduced so as to improve the clinical application quality and the safety of the children medication are improved.

The present invention relates to a children type azlocillin sodium pharmaceutical composition, especially to a combination application package, wherein the composition is an azlocillin sodium and low-sodium carrier infusion pharmaceutical combination preparation, which comprises azlocillin sodium for injection and a low-sodium carrier infusion, wherein the low-sodium carrier infusion contains a glucose and sodium chloride injection (15-200:1), a glucose, sodium chloride and potassium chloride injection (15-200:1:0-1) and the like. According to the present invention, the clinical application steps are simplified compared with the compatible mixing use of the azlocillin sodium and the low-sodium carrier infusion; and the clinical risk caused by the excessive sodium positioned in the blood and incapable of being metabolized due to the children kidney achieving the immature development state is reduced so as to improve the clinical application quality and the safety of the children medication are improved.

The present invention relates to a children type sulbenicillin sodium pharmaceutical composition, especially to a combination application package, wherein the composition is a sulbenicillin sodium and low-sodium carrier infusion pharmaceutical combination preparation, which comprises sulbenicillin sodium for injection and a low-sodium carrier infusion, wherein the low-sodium carrier infusion contains a glucose and sodium chloride injection (15-200:1), a glucose, sodium chloride and potassium chloride injection (15-200:1:0-1) and the like. According to the present invention, the clinical application steps are simplified compared with the compatible mixing use of the sulbenicillin sodium and the low-sodium carrier infusion; and the clinical risk caused by the excessive sodium positioned in the blood and incapable of being metabolized due to the children kidney achieving the immature development state is reduced so as to improve the clinical application quality and the safety of the children medication are improved.

The invention relates to a cefmenoxime hydrochloride drug composition for children, namely, a drug composition preparation of cefmenoxime hydrochloride and a low-sodium carrier infusion solution, in particular to a composition application package. The composition comprises the cefmenoxime hydrochloride and the low-sodium carrier infusion solution for injection. The low-sodium carrier infusion solution comprises a dextrose and sodium chloride injection (15-200:1), a glucose, sodium chloride and potassium chloride injection (15-200:1:0-1) and the like. Relative to the compatible and mixed use of the cefmenoxime hydrochloride and the low-sodium carrier infusion solution, clinical application steps are simplified. The clinical risks caused due to the fact that the kidneys of the children are not mature and are incapable of metabolizing too much sodium existing in blood are reduced. The clinical application quality and safety of child drugs are improved.

The invention discloses a method for simultaneously measuring the content of dextrose, chlorine and sodium in sodium chloride and dextrose injection through HPLC-CAD (High Performance Liquid Chromatography- Corona Chaged Aerosol Detection) with advantages of measurement accuracy and simplicity in operation, belongs to the field of chemical detection and aims to provide a detection method which is accurate in measurement and simple in operation. The method sequentially comprises the following steps: 1) preparing a test solution, namely fixing the volume of 1ml of sodium chloride and dextrose injection to 1000ml with water, uniformly shaking, and filtering to obtain the solution; 2) preparing a reference solution, namely precisely weighing 12.5g of dextrose reference substance and 2.25g of sodium chloride reference substance, adding into a 250mL of measuring bottle, adding water for dissolving and diluting to scales, and uniformly shaking so as to obtain the reference solution; and 3) analyzing by using high performance liquid chromatography. The method can replace a traditional detection method for simultaneously measuring the content of dextrose, chlorine and sodium in the sodium chloride and dextrose injection.

The invention relates to a childhood cefodizime sodium pharmaceutical composition, namely a pharmaceutical composition preparation of cefodizime sodium and low-sodium carrier transfusion, and in particular relates to a combined application package. The pharmaceutical composition comprises cefodizime sodium for injection and low-sodium carrier transfusion; the low-sodium carrier transfusion comprises a sodium chloride and dextrose injection ((15-200) to 1), a glucose and sodium chloride potassium chloride injection ((15-200) to 1 to (0-1)) and the like. Compared with combined and mixed application of the cefodizime sodium for injection and the low-sodium carrier transfusion, the clinical application steps are simplified; the clinical risk caused by immature development of kidneys of children and no metabolic capability on excessive sodium in blood is reduced; and the clinical application quality and safety of medicines for children are improved.

The invention relates to an alkalescent sodium chloride and dextrose injection medicinal composition. The alkalescent sodium chloride and dextrose injection medicinal composition contains glucose, sodium chloride, potassium chloride, tris(hydroxymethyl)aminoethane and water.

The invention relates to the technical field of medicinal preparation, and discloses a method for preparing a sodium chloride and dextrose injection. The method comprises the following steps: (a) adding sodium chloride and glucose into 60% to 70% configuration amount of water for injection to prepare a concentrated compound fluid; (b) adding the concentrated compound fluid into the water for injection until configuration amount, and carrying out potting to obtain potted liquid medicine; and (c) carrying out sterilization treatment on the potted liquid medicine, wherein the sterilization treatment comprises irradiation and/or microwave sterilization. According to the method, sterilization is carried out by using the sodium chloride and dextrose injection after irradiation and/or microwave potting, and killing of bacteria inside a sodium chloride injection can be realized without using a conventional moist heat sterilization method of increasing the temperature of the liquid medicine, the reduction of the clarity of the sodium chloride injection caused by boiling of the liquid medicine cannot be caused, and simultaneously, the content of 5-hydroxymethyl furfural inside the injectionis reduced, and the quality of the medicine is guaranteed.

The invention relates to a child type piperacillin tazobactam sodium pharmaceutical composition, namely a piperacillin tazobactam sodium and low-sodium carrier pharmaceutical composited preparation for transfusion, in particular to combined application package. The pharmaceutical composition comprises piperacillin tazobactam sodium for injection and a low-sodium carrier for transfusion. The low-sodium carrier for transfusion comprises sodium chloride and dextrose injection (15-200:1), glucose and sodium chloride potassium chloride injection (15-200:1:0-1) and the like. Compared with compatible and mixed use of piperacillin tazobactam sodium and the low-sodium carrier, clinical application steps are simplified; the clinical risk which is caused by the problem that the kidneys of children are not mature and have no capacity of metabolizing excessive sodium in blood is reduced, and clinical application quality and safety of pediatric drugs are improved.

The invention relates to a child-type medicinal composition with ceftizoxime sodium, i.e. a medicinal combined preparation with ceftizoxime sodium and low-sodium carrier infusion fluid, especially combined application package comprising the ceftizoxime sodium and the low-sodium infusion carrier fluid. The low-sodium carrier infusion fluid comprises glucose and sodium chloride injection fluid (15-200:1) and glucose and sodium-chloride potassium-chloride injection fluid (15-200:10-1) and the like. The child-type medicinal composition has the advantages that compared with the compatible and mixing use of the ceftizoxime sodium and the low-sodium carrier infusion fluid, the clinical application steps are simplified, the clinical risks caused by incapability of metabolizing excessive sodium in blood since the kidney of a child is not matured are reduced and the clinical application quality and safety of child administration are improved.